IMPACT Medicom

IMPACT Medicom

By IMPACT MedicomScience
Download on the App Store

IMPACT Medicom episodes

  • Precision Medicine in Oncology: Ep.2 Access to Genomic Profiling in British Columbia

    In this episode of IMPACT Medicom’s podcast series on Precision Medicine in Oncology we discuss:

    ·       The BC OncoPanel, a comprehensive genomic profiling (CGP) test available to patients with some cancers in British Columbia; 

    ·       The challenges for including CGP in laboratory budgets; 

    ·       The information exchange needed between stakeholders to accelerate access to CGP; and

    ·       How IMPACT Medicom’s CGP prioritization report can provide decision-makers with a framework for implementing CGP testing. 

    Our guests:
    Dr. Howard Lim is a Medical Oncologist at BC Cancer Agency and Clinical Associate Professor in the Faculty of Medicine at the University of British Columbia. He completed his medical oncology training at the BC Cancer Agency and received additional training at the Oregon Health Sciences University, specializing in gastrointestinal malignancies. Dr. Lim is actively involved in clinical trials, ethics, and genomic-based research.

    Jim Slater [MLT(ART), BSc, MBA] began his career as a medical laboratory technician in BC and has since worked in all four Western provinces in the area of diagnostic services. His past leadership roles include Executive Director of all diagnostics in Saskatchewan, Chief Executive Officer of all diagnostic services in Manitoba, and most recently, Chief Provincial Diagnostics Officer at the Provincial Health Services Authority in BC. Jim currently provides Health System and Business Consulting services, with expertise in precision medicine (genomics), value-based healthcare, innovation and resource stewardship, research, and business development. 

    Howard and Jim both served as steering committee members on IMPACT Medicom’s CGP prioritization report. The full report can be downloaded at:
    https://www.impactmedicom.com/publications/reports. 

     

    This podcast episode is sponsored by AstraZeneca Canada.  


     If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.



    35 min
  • Precision Medicine in Oncology Series: Episode 1 - Introduction with Dr. Sandeep Sedhev

    Welcome to our podcast series on precision medicine in oncology.  In this first episode of the series, we discuss the importance of comprehensive genomic profiling (CGP) as a critical tool for treating patients with advanced solid tumors.

    Included is a discussion of:

    • The CGP report, which is designed to aid Canadian decision makers in the prioritization of funding access to CGP testing in patients with solid tumors. 
    • The full report can be downloaded at:
      https://www.impactmedicom.com/publications/reports. 

    Our guest:
    Dr. Sandeep Sehdev is a Medical Oncologist and Clinical Investigator at the Ottawa Hospital Cancer Centre. Dr. Sehdev served as a steering committee member in the development of the CGP report and is passionate about medical education, the application of technology in oncology, and patient advocacy.

    If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.




    30 min
  • BTK Inhibitors for the Treatment of CLL: Are they all the same?

    In this episode, we discuss the use of Bruton’s Tyrosine Kinase (BTK) inhibitors for the treatment of patients with chronic lymphocytic leukemia (CLL). 

    Included is a discussion of:

    • Novel treatments for CLL
    • The impact of BTK inhibitors for the treatment of CLL
    • The differences between first- (e.g. ibrutinib) and second-generation (e.g. acalabrutinib, zanubrutinib, tirabrutinib) BTK inhibitors
    • Preliminary results from the ELEVATE-RR trial comparing the efficacy and safety of acalabrutinib vs ibrutinib in high-risk relapsed/refractory CLL (see: https://www.cancernetwork.com/view/acalabrutinib-meets-primary-end-point-versus-ibrutinib-in-previously-treated-high-risk-cll for the full press release)


    Our guest:
    Dr. Carolyn Owen is an Associate Professor in the Division of Hematology & Hematological Malignancies at the University of Calgary. She completed her internal medicine training in Ottawa, followed by Hematology training in Vancouver and a research fellowship in molecular genetics at Barts and the London School of Medicine. Her current clinical interests are in the areas of low-grade lymphoma and chronic lymphocytic leukemia (or CLL) and she is the local principal investigator at the Tom Baker Cancer Centre for a number of clinical trials focusing on these areas.

     

    Funding for this episode provided by AstraZeneca, Canada. If you in enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.

    29 min
  • Chronic Lymphocytic Leukemia (CLL): How do we Manage Patients During COVID-19?

    In this episode we discuss the management of CLL patients during the COVID-19 pandemic. 

    Included is a discussion of:

    • The initial treatment of patients with CLL during COVID-19
    • The use of BTK inhibitors vs FCR
    • The use of intravenous or subcutaneous immunoglobulin
    • Existing guidelines for the treatment of CLL during COVID-19
    • The virtual management of CLL patients

    Our guest:

    Dr. Pavic
    is a Medical Oncologist and Chief of the Hemato-Oncology department at the Centre intégré universitaire de santé et de services sociaux de l’Estrie – Centre Hospitalier Universitaire de Sherbrooke and an assistant professor in the Faculty of Medicine and Health Sciences at the Université de Sherbrooke.

    Guidelines

    • ASH recommendations: https://www.hematology.org/covid-19/covid-19-and-cll
    • Canadian recommendations:  Management of chronic lymphocytic leukemia in Canada during the coronavirus pandemic: L.H. Sehn,  P. Kuruvilla, A. Christofides, J. Stakiw https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339858/pdf/conc-27-e332.pdf

    **If you enjoy our podcast, please take the time to rate our podcast and subscribe**

    For more great podcasts and other features, visit our website at: www.impactmedicom.com. 

    20 min
  • Virtual Patient Management during COVID-19: How can we best Manage Patients with Inflammatory Arthritis?

    On today’s podcast episode, we discuss the virtual management of patients with inflammatory arthritis. 

    We are joined by:

    •  Dr. Janet Pope: Professor of Medicine in the Division of Rheumatology, Epidemiology and Biostatistics at the University of Western Ontario. 


    Our episode includes a discussion of:

    • The use of a virtual platform for managing patients with inflammatory arthritis. 
    • Which patients should  be seen in person rather than virtually.
    • Barriers to virtual assessment, including measuring swollen and tender joints, co-morbidities, and overall health. 
    • Patient barriers to virtual care such as familiarity with technology, language barriers, memory issues, etc...
    • Whether there are disease-related risk factors for patients with inflammatory arthritis. 
    • Treatment modifications such as whether we should "treat-to-target" and if modifications are needed during the COVID-19 pandemic. 


    **If you enjoy our podcast, please take the time to rate our podcast and subscribe**

    For more great podcasts and other features, visit our website at: www.impactmedicom.com. 

    25 min
  • The Opioid Epidemic in Canada: What Can We Do?

    In this episode, we discuss the opioid epidemic in Canada and the use of naloxone, a life-saving drug that is used to prevent death from opioid overdose, with pharmacists: Dr. Ross Tsuyuki and Mark Barnes. 

    • Dr. Ross Tsuyuki - professor and chair of the Department of Pharmacology in the Faculty of Medicine and Dentistry at the University of Alberta.
    • Mark Barnes  - owner of Respect Rx  Pharmacies in Ottawa.


    Our episode includes a discussion of:

    • The extent of the opioid epidemic in Canada and how COVID-19 has impacted the number of opioid-related deaths.
    • The use of the drug, naloxone, to prevent death from respiratory depression caused by opioid overdose. Naloxone is distributed as a nasal spray or injection kit and is supplied by pharmacists. 
    • The unique role of pharmacists in the distribution of naloxone  for the fight against the opioid epidemic. 
    • Who should be given a naloxone kit and its relevance in general for anyone prescribed opioids. 
    • The development of the first published guidelines for Canadian pharmacists on prescribing naloxone. The guidelines  can be found here: https://journals.sagepub.com/doi/pdf/10.1177/1715163520949973. 


    **If you enjoy our podcast, please take the time to rate our podcast and subscribe**

    For more great podcasts and other features, visit our website at: www.impactmedicom.com. 

    29 min
  • COVID-19: Playing Sports Safely with Dr. Ray Deonandan

    Dr. Ray Deonandan is a Canadian epidemiologist, assistant director, and associate professor at the University of Ottawa. In this episode, we discuss how we can exercise safely during the COVID-19 epidemic as the cold weather approaches.

    • The importance of exercise for physical and mental health is discussed as well as tips for reducing the chance of COVID-19 transmission while exercising. 
    • We discuss the differences in transmission risk for adults vs children and the types of exercises that are safest for each age group. 
    • Topics such as whether we should wear a mask outside while exercising, whether sweat droplets increase transmission, and the length of exposure needed for transmission outside are discussed. 


    **If you enjoy our podcast, please take the time to rate our podcast and subscribe**
    For more great podcasts and other features, visit our website at: www.impactmedicom.com. 

    27 min

About IMPACT Medicom

From the publisher's feed

We are a medical communications company with a passion for developing high-quality content. We write & design content for healthcare professionals and patients in a variety of therapeutic…

More shows like IMPACT Medicom

The Daily by The New York Times

The Daily

112,262 Listeners